Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy

Medical Hypotheses

Volumn 82, Issue 3, 2014, Pages 295-299

  Ströhlein, Michael Alfred ^a   Lefering, Rolf ^a   Bulian, Dirk Rolf ^a   Heiss, Markus Maria ^a  

^a UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANTIBODIES, BISPECIFIC; FEMALE; HUMANS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; PROGNOSIS; ROC CURVE;

EID: 84893920163     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.12.014     Document Type: Article

References (19)

1. Adam R.A., Adam Y.G. Malignant ascites: past, present, and future. J Am Coll Surg 2004, 198(6):999-1011. S1072-7515(04)00190-5 [pii]. 10.1016/j.jamcollsurg.2004.01.035.
2. Chu D.Z., Lang N.P., Thompson C., Osteen P.K., Westbrook K.C. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989, 63(2):364-367.
3. Sadeghi B., Arvieux C., Glehen O., Beaujard A.C., Rivoire M., Baulieux J., et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000, 88(2):358-363. [pii]. 10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O.
4. Heiss M.M., Murawa P., Koralewski P., Kutarska E., Kolesnik O.O., Ivanchenko V.V., et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. Int J Cancer 2010, 10.1002/ijc.25423.
5. Heiss M.M., Strohlein M.A., Jager M., Kimmig R., Burges A., Schoberth A., et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005, 117(3):435-443. 10.1002/ijc.21165.
6. Seimetz D., Lindhofer H., Bokemeyer C. Development and approval of the trifunctional antibody catumaxomab (anti-EpCAMxanti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 2010, S0305-7372(10)00041-1 [pii]. 10.1016/j.ctrv.2010.03.001.
7. Ströhlein M.A., Lordick F., Rüttinger D., Grützner K.U., Schemanski O.C., Jäger M., et al. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, Phase I/II Trail. Onkologie 2011, 34(3):101-110.
8. Zeidler R., Mysliwietz J., Csanady M., Walz A., Ziegler I., Schmitt B., et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000, 83(2):261-266. S0007092000912370 [pii]. 10.1054/bjoc.2000.1237.
9. Zeidler R., Reisbach G., Wollenberg B., Lang S., Chaubal S., Schmitt B., et al. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999, 163(3):1246-1252. ji_v163n3p1246 [pii].
10. Arapis K., Caliandro R., Stern J.B., Girard P., Debrosse D., Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients. Surg Endosc 2006, 20(6):919-923. 10.1007/s00464-005-0534-6.
11. Went P.T., Lugli A., Meier S., Bundi M., Mirlacher M., Sauter G., et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol 2004, 35(1):122-128. S0046817703005021 [pii].
12. Ruf P., Gires O., Jager M., Fellinger K., Atz J., Lindhofer H. Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer. Br J Cancer 2007, 97(3):315-321. 10.1038/sj.bjc.6603881.
13. Ruf P., Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001, 98(8):2526-2534.
14. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228-247. S0959-8049(08)00873-3 [pii]. 10.1016/j.ejca.2008.10.026.
15. Jager M., Schoberth A., Ruf P., Hess J., Hennig M., Schmalfeldt B., et al. Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3). Cancer Res 2012, 72(1):24-32. 10.1158/0008-5472.can-11-2235.
16. Zeidler R., Mayer A., Gires O., Schmitt B., Mack B., Lindhofer H., et al. TNFalpha contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 2001, 21(5):3499-3503.
17. Cho H., Hur H.W., Kim S.W., Kim S.H., Kim J.H., Kim Y.T., et al. Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2009, 58(1):15-23. 10.1007/s00262-008-0516-3.
18. Shimada H., Takiguchi N., Kainuma O., Soda H., Ikeda A., Cho A., et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010, 13(3):170-176. 10.1007/s10120-010-0554-3.
19. An X., Ding P.R., Wang F.H., Jiang W.Q., Li Y.H. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 2011, 32(2):317-324. 10.1007/s13277-010-0124-7.